KOREA WHO
-
-
-
Inside Director of Hanmi Science and Nominee for CEO of Hanmi Pharmaceutical
Lim Jong-yun
Victory in Management Dispute with Mother, Returning to Management, Inheritance Tax and Investment Attraction as Challenges
-
Last Updated on May 21, 2024
-
Inside Director of Hanmi Science and Nominee for CEO of Hanmi Pharmaceutical
Life Summary
Lim Jong-yun is an inside director of Hanmi Science.
Soon, he will be appointed as the CEO of Hanmi Pharm after an extraordinary general meeting and board meeting of Hanmi Pharm.
Born in 1972 as the eldest son among two sons and one daughter of the late Lim Sung-ki, former chairman of Hanmi Pharm Group.
He graduated from Boston College with a degree in biochemistry and pursued a master's degree in jazz composition at Berklee College of Music.
He joined Hanmi Pharm as a manager in the strategic team and served as the general manager (president) of Beijing Hanmi Pharm.
He became the president of Hanmi Pharm and, along with his father, Chairman Lim Sung-ki, was appointed co-CEO of the holding company Hanmi Holdings when Hanmi Pharm transitioned to a holding company system.
Hanmi Holdings was renamed Hanmi Science, and as Lim Sung-ki stepped down as an inside director, Lim Jong-yun became the sole CEO of Hanmi Science.
He and his mother, Song Young-sook, who is the chairman of Hanmi Pharm Group, were co-CEOs until a management dispute arose within Hanmi Pharm Group in January 2024, leading to his dismissal as president.
However, he returned to management by being appointed as an inside director at the shareholders' meeting held the same year.
He is now working on resolving the inheritance tax issues that arose during the management dispute and attracting investments for the contract research organization (CRO) or contract development organization (CDO) business in biopharmaceuticals.
He prioritizes practical thinking and emphasizes open communication with employees.
Keywords
#LimJongyun #HanmiScience #HanmiPharm #CEO #inheritancetax #investment #biopharmaceuticals #CRO #CDO #managementdispute
Soon, he will be appointed as the CEO of Hanmi Pharm after an extraordinary general meeting and board meeting of Hanmi Pharm.
Born in 1972 as the eldest son among two sons and one daughter of the late Lim Sung-ki, former chairman of Hanmi Pharm Group.
He graduated from Boston College with a degree in biochemistry and pursued a master's degree in jazz composition at Berklee College of Music.
He joined Hanmi Pharm as a manager in the strategic team and served as the general manager (president) of Beijing Hanmi Pharm.
He became the president of Hanmi Pharm and, along with his father, Chairman Lim Sung-ki, was appointed co-CEO of the holding company Hanmi Holdings when Hanmi Pharm transitioned to a holding company system.
Hanmi Holdings was renamed Hanmi Science, and as Lim Sung-ki stepped down as an inside director, Lim Jong-yun became the sole CEO of Hanmi Science.
He and his mother, Song Young-sook, who is the chairman of Hanmi Pharm Group, were co-CEOs until a management dispute arose within Hanmi Pharm Group in January 2024, leading to his dismissal as president.
However, he returned to management by being appointed as an inside director at the shareholders' meeting held the same year.
He is now working on resolving the inheritance tax issues that arose during the management dispute and attracting investments for the contract research organization (CRO) or contract development organization (CDO) business in biopharmaceuticals.
He prioritizes practical thinking and emphasizes open communication with employees.
Keywords
#LimJongyun #HanmiScience #HanmiPharm #CEO #inheritancetax #investment #biopharmaceuticals #CRO #CDO #managementdispute